Literature DB >> 23608817

Specificities of lung adenocarcinoma in women who have never smoked.

Julien Mazières1, Isabelle Rouquette, Benoit Lepage, Julie Milia, Laurent Brouchet, Nicolas Guibert, Michèle Beau-Faller, Pierre Validire, Paul Hofman, Pierre Fouret.   

Abstract

INTRODUCTION: No clear data are available on the high rate of tobacco-independent lung cancer in women. We hypothesize that genetic events or hormonal factors may be partly involved.
METHODS: We aimed to compare clinical, pathological, and biological characteristics of lung cancer in two cohorts of women: smokers and never-smokers. A total of 140 women (63 never-smokers and 77 former/current smokers) with adenocarcinoma, were included in this study.
RESULTS: The never-smokers were characterized by a higher age (67 versus 58.7 years; p < 0.0001) and a higher frequency of lepidic features (60.3% versus 37.7%; p = 0.008) compared with smokers. We observed differential genetic alteration repartition in women according to their tobacco status: 50.8% of never-smokers displayed an epidermal growth factor receptor (EGFR) mutation versus 10.4% of smokers (p < 0.001). In contrast, K-Ras was more frequently mutated in smokers (33.8%) than in never-smokers (9.5%; p = 0.001). We also observed a higher percentage of estrogen receptors (ER) α expression (p = 0.03; and p = 0.008 with two different antibodies) in patients who never smoked when compared with smokers. There was no significant difference in ERβ and progesterone receptors between the groups. Finally, ERα expression was correlated with the presence of an EGFR mutation.
CONCLUSIONS: This study suggests that when lung cancer occurs in women who have never smoked, it is more frequently associated with an EGFR mutation and ERα expression, with a correlation between both markers. These findings underline the possibility of treating women who have never smoked by targeting both hormonal factors and genetic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23608817     DOI: 10.1097/JTO.0b013e3182904dfb

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  13 in total

1.  Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Authors:  Timothy F Burns; Laura P Stabile
Journal:  Lung Cancer Manag       Date:  2014-02-01

Review 2.  Estrongenic steroid hormones in lung cancer.

Authors:  Jill M Siegfried; Laura P Stabile
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

3.  Exon 7 splicing variant of estrogen receptor α is associated with pathological invasiveness in smoking-independent lung adenocarcinoma.

Authors:  Ayumi Suzuki; Katsuhiro Okuda; Motoki Yano; Risa Oda; Tadashi Sakane; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Makoto Nakanishi; Ryoichi Nakanishi
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

Review 4.  Smoking out reproductive hormone actions in lung cancer.

Authors:  Jill M Siegfried
Journal:  Mol Cancer Res       Date:  2014-01-07       Impact factor: 5.852

Review 5.  Influence of estrogen in non-small cell lung cancer and its clinical implications.

Authors:  Vianey Rodriguez-Lara; Juan-Manuel Hernandez-Martinez; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 6.  Lung cancer in women: an overview with special focus on Spanish women.

Authors:  J Remon; E Molina-Montes; M Majem; P Lianes; D Isla; P Garrido; E Felip; N Viñolas; J de Castro; A Artal; M-J Sánchez
Journal:  Clin Transl Oncol       Date:  2013-11-26       Impact factor: 3.405

Review 7.  Exploring estrogenic activity in lung cancer.

Authors:  Bartosz Kazimierz Słowikowski; Margarita Lianeri; Paweł Piotr Jagodziński
Journal:  Mol Biol Rep       Date:  2016-10-25       Impact factor: 2.316

8.  Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma.

Authors:  Dakai Xiao; Hui Pan; Fuqiang Li; Kui Wu; Xin Zhang; Jianxing He
Journal:  Oncotarget       Date:  2016-04-19

9.  Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA.

Authors:  Kevin Washetine; Mehdi Kara-Borni; Simon Heeke; Christelle Bonnetaud; Jean-Marc Félix; Lydia Ribeyre; Coraline Bence; Marius Ilié; Olivier Bordone; Marine Pedro; Priscilla Maitre; Virginie Tanga; Emmanuelle Gormally; Pascal Mossuz; Philippe Lorimier; Charles Hugo Marquette; Jérôme Mouroux; Charlotte Cohen; Sandra Lassalle; Elodie Long-Mira; Bruno Clément; Georges Dagher; Véronique Hofman; Paul Hofman
Journal:  Cancers (Basel)       Date:  2018-06-11       Impact factor: 6.639

10.  Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Authors:  Kevin Washetine; Simon Heeke; Christelle Bonnetaud; Mehdi Kara-Borni; Marius Ilié; Sandra Lassalle; Catherine Butori; Elodie Long-Mira; Charles Hugo Marquette; Charlotte Cohen; Jérôme Mouroux; Eric Selva; Virginie Tanga; Coraline Bence; Jean-Marc Félix; Loic Gazoppi; Taycir Skhiri; Emmanuelle Gormally; Pascal Boucher; Bruno Clément; Georges Dagher; Véronique Hofman; Paul Hofman
Journal:  Cancers (Basel)       Date:  2018-06-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.